摘要
目的探讨维立西呱对心力衰竭合并慢性肾功能不全的非糖尿病患者的临床疗效。方法选取2022年1月至2023年9月丰城市人民医院收治的80例心力衰竭合并慢性肾功能不全的非糖尿病患者作为研究对象,以随机数字表法分为观察组与对照组,每组40例。对照组采用利尿剂与美托洛尔缓释片治疗,观察组在对照组的基础上加用维立西呱治疗。比较两组治疗前后血清电解质、氨基末端脑钠肽前体(N-terminal pro-brain natriuretic peptide,NT-ProBNP)水平、6 min步行试验(6 min walk test,6-MWT)、心功能指标[左心室射血分数(left ventricular ejection fraction,LVEF)、左心室舒张末期内径(left ventricular end diastolic dimension,LVEDD)与左心室收缩末期内径(left ventricular end systolic diameter,LVESD)]、肾功能指标[血肌酐(serum creatinine,SCr)、肾小球滤过率(estimated glomerular filtration rate,eGFR)]及用药不良反应发生情况。结果两组治疗前后血清K+、Na+水平比较差异无统计学意义。治疗后,两组NT-ProBNP水平低于治疗前,且观察组低于对照组,两组6-MWT大于治疗前,且观察组大于对照组,差异有统计学意义(P<0.05)。治疗后,两组LVEF高于治疗前,且观察组高于对照组,两组LVEDD、LVESD均短于治疗前,且观察组短于对照组,差异有统计学意义(P<0.05)。治疗后,两组SCr水平低于治疗前,且观察组低于对照组,两组eGFR均高于治疗前,且观察组高于对照组,差异有统计学意义(P<0.05)。两组用药不良反应发生率比较差异无统计学意义。结论维立西呱在心力衰竭合并慢性肾功能不全的非糖尿病患者的治疗中具有良好的应用表现,可有效改善患者心功能、肾功能,且不会增加药物不良反应发生风险。
Objective To explore the clinical efficacy of vericiguat in the treatment of non-diabetic patients with heart failure complicated with chronic renal insufficiency.Methods A total of 80 non-diabetic patients with heart failure complicated with chronic renal insufficiency admitted to Fengcheng People's Hospital from January 2022 to September 2023 were selected as the research subjects,and they were randomly divided into the observation group and the control group by random number table method,with 40 cases in each group.The control group was treated with diuretics and metoprolol sustained-release tablets,while the observation group was treated with vericiguat on the basis of the control group.The levels of serum electrolytes,N-terminal pro-brain natriuretic peptide(NT-ProBNP),6 min walk test(6-MWT),cardiac function indicators(left ventricular ejection fraction[LVEF],left ventricular end-diastolic diameter[LVEDD],and left ventricular end-systolic diameter[LVESD]),renal function indicators(serum creatinine[SCr],estimated glomerular filtration rate[eGFR]),and the occurrence of adverse drug reactions were compared between the two groups before and after treatment.Results There was no statistically significant difference in the levels of serum K+and Na+between the two groups before and after treatment.After treatment,the NT-ProBNP levels of the two groups were lower than those before treatment,and the observation group was lower than the control group,and the differences were statistically significant(P<0.05).The 6-MWT of the two groups was greater than that before treatment,and the observation group was greater than the control group,and the differences were statistically significant(P<0.05).After treatment,the LVEF of the two groups was higher than that before treatment,and the observation group was higher than the control group;the LVEDD and LVESD of the two groups were shorter than those before treatment,and the observation group was shorter than the control group,and the differences were statistically significant(P<0.05).After treatment,the SCr levels of the two groups were lower than those before treatment,and the observation group was lower than the control group;the eGFR of the two groups was higher than that before treatment,and the observation group was higher than the control group,and the differences were statistically significant(P<0.05).There was no statistically significant difference in the incidence of adverse drug reactions between the two groups.Conclusion Vericiguat has good application performance in the treatment of non-diabetic patients with heart failure complicated chronic renal insufficiency,and can effectively improve cardiac and renal functions without increasing the risk of adverse drug reactions.
作者
聂贞蕴
黄磊
王瑶
NIE Zhenyun;HUANG Lei;WANG Yao(Department of Cardiovascular Medicine,Fengcheng People's Hospital,Fengcheng,Jiangxi,331100,China)
出处
《当代医学》
2025年第14期38-42,共5页
Contemporary Medicine
基金
江西省卫生健康委科技计划项目(202410919)。
关键词
维立西呱
心力衰竭
慢性肾功能不全
心功能
Vericiguat
Heart failure
Chronic renal insufficiency
Cardiac function
